Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long alternative to intravitreal injections.

Robert L. Rohn has an experienced backdrop of support. The three listed managers boast 14 years of average listed portfolio management experience. As a team, they manage seven investment vehicles ...